



CASE PR/4-32412A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV722485282US

Express Mail Label Number

June 30, 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LE GRAND ET AL.

APPLICATION NO: 10/507,139

FILED: SEPTEMBER 9, 2004

FOR: AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists applicant Clive McCarthy's residence and the Foreign Application filing date. Please issue a corrected filing receipt listing the applicant Clive McCarthy's residence and the Foreign Application filing date as follows:

--Applicant(s)

Clive McCarthy, Basel, SWITZERLAND


Foreign Applications

UNITED KINGDOM 0206218.0 03/15/2002--

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614  
Date: 6/30/05




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPL NO.   | FILING OR 371<br>(c) DATE | ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|-----------------|----------|----------|----------|
| 10/507,139 | 09/09/2004                | 1614     | 938           | PR/4-32412A     |          | 21       | 1        |

1095  
NOVARTIS  
CORPORATE INTELLECTUAL PROPERTY  
ONE HEALTH PLAZA 104/3  
EAST HANOVER, NJ 07936-1080



CONFIRMATION NO. 8975

## FILING RECEIPT



\*OC000000015991891\*

Date Mailed: 05/18/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Darren Mark Le Grand, West Sussex, UNITED KINGDOM;  
Clive McCarthy, ~~Novartis~~, UNITED KINGDOM; Basel, SWITZERLAND  
Clive Victor Walker, Horsham, UNITED KINGDOM;  
John James Woods, Horsham, UNITED KINGDOM;

**Power of Attorney:** The patent practitioners associated with Customer Number 1095.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/02715 03/14/2003

## Foreign Applications

03  
UNITED KINGDOM 0206218.0 05/15/2002  
UNITED KINGDOM 0229627.5 12/19/2002

**Projected Publication Date:** 08/18/2005

**Non-Publication Request:** No

**Early Publication Request:** No

receipt  
IFW

**Title**

Azetidine derivatives as ccr-3 receptor antagonists

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).